The Role of B Cells in Multiple Sclerosis: Implications for B-Cell-Targeted Therapy
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system. Although most studies have emphasized the role of T cells in the pathogenesis of MS, increasing evidence supports the concept that B cells play a key role in the pathogenesis of MS, mainly in association with the deposition of antibodies and the activation of complement. Emerging pathophysiological findings of B-cell, follicle-like structures in the meninges of patients and observations of decreased interleukin (IL)-10 production from naive B cells in MS have recently been reported. As more knowledge is gained of the pathophysiology of B cells in MS, the mechanisms of B-cell-mediated neuropharmacology of current therapy had been clarified as well. In this article, we review the increasing evidence that points to a link between B cells and MS, and also discuss the potential of B-cell-targeted therapy in MS.
No Supplementary Data
No Article Media
Document Type: Research Article
Affiliations: Department of Neurology, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kitaku, Sapporo 060-8638 Japan.
Publication date: 2010-09-01
More about this publication?
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.